In patients with biopsy-proven MASH, efruxifermin reduced liver fat by up to 72% after 12 weeks and pegozafermin reduced liver fat by up to 48% after 24 weeks (both FGF21 analogs)16,17. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.